Maarten van der Doelen

Patient-reported outcomes in mCRPC patients treated with radium-223 therapy

Timepoint T1 versus T0

Timepoint T2 versus T0

Cognitive functioning

Cognitive functioning

Total cohort

Total cohort

Subgroup 6 injections

Subgroup 6 injections

Subgroup 4-5 injections

Subgroup 4-5 injections

Subgroup 1-3 injections

-50 -40 -30 -20 -10

0 10 20 30

-50 -40 -30 -20 -10

0 10 20 30

Mean difference (95% CI) from baseline

Mean difference (95% CI) from baseline

Social functioning

Social functioning

Total cohort

Total cohort

Subgroup 6 injections

Subgroup 6 injections

4

Subgroup 4-5 injections

Subgroup 4-5 injections

Subgroup 1-3 injections

-50 -40 -30 -20 -10

0 10 20 30

-50 -40 -30 -20 -10 0 10 20 30 Mean difference (95% CI) from baseline

Mean difference (95% CI) from baseline

Supplementary figure 5. Mean difference in scores from baseline in cancer-specific health-related quality of life (EORTC QLQ-C30 functional scales and global health status), comparing time point T1 to T0 (N=114) and T2 to T0 (N=91). Bars indicate the mean difference with 95% confidence intervals.

113